A Kalcijs D3

A Kalcijs D3 Uses, Dosage, Side Effects, Food Interaction and all others data.

A Kalcijs D3 when taken with meals, combines with dietary phosphate to form insoluble Calcium Phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. A Kalcijs D3 is highly soluble at neutral pH, making the Calcium readily available for binding to phosphate in the proximal small intestine. Orally administered A Kalcijs D3 from pharmaceutical dosage forms has been demonstrated to be systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under non fasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions.

Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.

A Kalcijs D3
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	A Kalcijs D3
Generic	Calcium Acetate
Calcium Acetate Other Names	Acetate of lime, Brown acetate of lime, Calcio acetato, Calcium acetate, calcium ethanoate, Gray acetate of lime, Lime acetate, Lime pyrolignite
Type
Formula	C₄H₆CaO₄
Weight	Average: 158.166 Monoisotopic: 157.989199835
Groups	Approved, Investigational
Therapeutic Class	Drugs for reduction of serum phosphorus in patients with ESRD, Minerals in bone formation, Specific mineral preparations
Manufacturer
Available Country	Latvia
Last Updated:	September 19, 2023 at 7:00 am

Uses

A Kalcijs D3 is used for the treatment of hyperphosphatemia, control of hyperphosphatemia in end stage renal failure.

A Kalcijs D3 is also used to associated treatment for these conditions: Hyperphosphataemia, High phosphate levels, Astringent, Prophylaxis of bacterial skin infections

How A Kalcijs D3 works

Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.

Dosage

A Kalcijs D3 dosage

Adult:Initially 3-4 g daily. Usual range: 6-12 g daily.

To control hyperphosphataemia in chronic renal failure: Initially 1.334 g (338 mg of calcium). May increase dosage gradually according to serum phosphate conc, provided hypercalcaemia does not occur.

Side Effects

In clinical studies, patients have occasionally experienced nausea during A Kalcijs D3 therapy. Hypercalcemia may occur during treatment with A Kalcijs D3. Mild hypercalcemia (Ca > 10.5 mg/dl) may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. More severe hypercalcemia (Ca>12mg/dl) is associated with confusion, delirium, stupor and coma. The long-term effect of A Kalcijs D3 on the progression of vascular or soft-tissue calcification has not been determined. Isolated cases of pruritus have been reported which may represent allergic reactions.

Toxicity

Oral, rat: LD₅₀ = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).

Precaution

Patients with end stage renal failure may develop hypercalcemia when given calcium with meals. No other calcium supplements should be given concurrently with A Kalcijs D3.

Interaction

A Kalcijs D3 may decrease the bioavailability of tetracycline.

Food Interaction

Take with food. When taken with food, calcium acetate forms an insoluble complex with the phosphorus from food, reducing phosphorus serum concentrations.

Elimination Route

40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.

Elimination Route

Calcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.

Pregnancy & Breastfeeding use

Animal reproduction studies have not been conducted with A Kalcijs D3. It is not known whether A Kalcijs D3 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. A Kalcijs D3 should be given to a pregnant woman only if clearly needed.

There are no adequate studies in women for determining infant risk when using the medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.